Amaroq unveils Black Angel revival plan

Simply Wall St reports Amaroq’s Q2 results showed a shift to profitability, with revenue of C$37.3m and net income of C$11.1m, versus a prior loss, and Basic EPS of C$0.0239. It also cites H1 gross profit of C$34.9m, liquidity around US$47m, and debt drawn on a revolving credit facility, while cost questions persist.

Amaroq Ltd. reported further underground drilling results from the Nalunaq Gold Mine in southern Greenland. The company said the Nalunaq Main Vein averaged 42.8 g/t Au, with 16 of 37 holes above 30 g/t and 30% above 60 g/t. It highlighted 132.5 g/t Au over 0.5 m and plans to drill untested western areas from the 810 exploration drive.

BAE Systems (BA.L) secured a $138M U.S. Navy contract for Virginia-class submarine propulsor assemblies, covering production, services, and parts until 2032. The company meets the Navy's annual production target and has supplied all submarines to date. Shares fell 1.36% to 1,891.50p on LSE.

Merck (MRK) and Moderna (MRNA) plan to file intismeran for melanoma this year, with trial data showing a 42% reduction in recurrence or death risk. Merck expects earnings guidance for 2027 on Feb. 2, with analysts forecasting flat EPS of $8.98. Keytruda, Merck's top-selling drug, faces patent expiration in 2028. Merck trades at 17.5x forward earnings, above its five-year average.

BAE Systems completed Lot 8 RF sensor deliveries to Lockheed Martin for the US military’s LRASM program, following investments in electronic warfare facilities. The sensors enable the missile to target ships in complex environments. BAE Systems is contracted to supply these sensors through 2028, with production expected to increase from 2026. The company also upgraded the sensor’s software to enhance capabilities.

Bank of America analyst Vivek Arya lowered his price target for Intel (INTC) to $80 from $100, citing uncertainty about its 2027 CPU business and lack of progress in securing external customers for its foundry operations. The Hold rating was maintained.